Research programme: antibody-coupled T-cell receptor therapeutics - Unum Therapeutics/Seattle Genetics

Drug Profile

Research programme: antibody-coupled T-cell receptor therapeutics - Unum Therapeutics/Seattle Genetics

Alternative Names: ACTR 707; Antibody-coupled T cell receptor + anti-GPC3 antibody; Antibody-coupled T cell receptor + humanized non-fucosylated anti-BCMA antibody; SEA-BCMA

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unum Therapeutics
  • Class Antibodies; Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action B-cell maturation antigen modulators; CD200 antigen inhibitors; Cell replacements; Glypican modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 23 Aug 2017 FDA approves IND application for ACTR 087 in Multiple myeloma (Second-line therapy or greater, Combination therapy)
  • 23 Aug 2017 Unum Therapeutics plans a phase I trial for Multiple myeloma (Second-line therapy or greater, Combination therapy) in USA in second half of 2017
  • 19 Jun 2017 US FDA approves IND application for ACTR 707 in B-cell lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top